Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;100(4):708-711.
doi: 10.1002/ajh.27591. Epub 2025 Jan 20.

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents

Giovanni Marconi  1 , Elisabetta Petracci  1 , Giuseppe Lanzarone  2 , Calogero Vetro  3   4 , Maria Paola Martelli  5 , Cristina Papayannidis  6 , Ernesta Audisio  7 , Paola Minetto  8 , Carola Riva  8 , Fabio Guolo  8 , Gianluca Martini  9 , Patrizia Zappasodi  10 , Federico Vincenzo  11 , Federica Gigli  12 , Davide Griguolo  13 , Michela Rondoni  14 , Giulia Ciotti  15 , Erika Borlenghi  16 , Nadia Ciccone  17 , Fanny Erika Palumbo  3 , Jacopo Nanni  6 , Daniele Mattei  18 , Massimo Bernardi  19 , Alessandro Cignetti  20 , Chiara Zingaretti  1 , Bernadette Vertogen  1 , Claudio Cerchione  1 , Francesco Lanza  14 , Daniela Cilloni  21 , Lorenzo Brunetti  22 , Raffaele Palmieri  23 , Antonio Curti  6 , Maria Benedetta Giannini  1 , Elisabetta Todisco  24 ; AVALON research group; Nicola Fracchiolla  25 , Giovanni Martinelli  1   6
Affiliations

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents

Giovanni Marconi et al. Am J Hematol. 2025 Apr.

Abstract

Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.

Keywords: AML; acute myeloid leukemia; fitness; low intensity therapy.

PubMed Disclaimer

Conflict of interest statement

GMarc received research funds from AbbVie, Astellas, AstraZeneca, Daiichi Sankyo, Pfizer, and Syros and was a consultant or was included in the speaker's bureau for AbbVie, Astellas, AstraZeneca, Immunogen, Janssen, Menarini/Stemline, Pfizer, Ryvu, Servier, Syros, and Takeda. FL received research funds from Pfizer and Alexion and is a consultant from Sobi, Roche, AbbVie, Amgen, and Novartis. MR was a consultant or was included in the speaker's bureau for Novartis, Gentili, Blueprint, and Jazz. GMartinelli is a consultant for AbbVie Inc., Celgene, Roche, Janssen, Astellas, Pfizer, and Incyte. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curves for OS by HCT‐CI (A) and augmented HCT‐CI (B) classes based on the median value.
See this image and copyright information in PMC

References

    1. Todisco E., Papayannidis C., Fracchiolla N., et al., “AVALON: The Italian Cohort Study on Real‐Life Efficacy of Hypomethylating Agents Plus Venetoclax in Newly Diagnosed or Relapsed/Refractory Patients With Acute Myeloid Leukemia,” Cancer 129, no. 7 (2023): 992–1004, 10.1002/CNCR.34608. - DOI - PubMed
    1. Ferrara F., Barosi G., Venditti A., et al., “Consensus‐Based Definition of Unfitness to Intensive and Non‐Intensive Chemotherapy in Acute Myeloid Leukemia: A Project of SIE, SIES and GITMO Group on a New Tool for Therapy Decision Making,” Leukemia 27, no. 5 (2013): 997–999, 10.1038/LEU.2012.303. - DOI - PubMed
    1. Apolito V., Arrigo G., Vasseur L., et al., “Validation of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality and Survival in Acute Myeloid Leukaemia Patients Treated With Hypomethylating Agents and Venetoclax,” British Journal of Haematology 203, no. 4 (2023): e98–e101, 10.1111/BJH.19022. - DOI - PubMed
    1. Döhner H., DiNardo C. D., Wei A. H., et al., “Genetic Risk Classification for Adults With AML Receiving Less‐Intensive Therapies: The 2024 ELN Recommendations,” Blood 144 (2024): 2169–2173, 10.1182/BLOOD.2024025409. - DOI - PubMed
    1. Bataller A., Bazinet A., DiNardo C. D., et al., “Prognostic Risk Signature in Patients With Acute Myeloid Leukemia Treated With Hypomethylating Agents and Venetoclax,” Blood Advances 8 (2023): 927–935, 10.1182/BLOODADVANCES.2023011757. - DOI - PMC - PubMed

LinkOut - more resources